High-level Expression of Interleukin-17 and C-reactive Protein Predicts Tumor Progression in Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
10.17998/jlc.2016.16.2.108
- Author:
Myeong Jun SONG
1
;
Sung Won LEE
;
Eun Jee OH
;
Bohyun JANG
;
Jeong Won JANG
;
Si Hyun BAE
;
Jong Young CHOI
;
Seung Kew YOON
Author Information
1. Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea.
- Publication Type:Original Article
- Keywords:
Chemoembolization;
Growth factors;
Cytokine;
Progression;
Survival
- MeSH:
C-Reactive Protein*;
Carcinoma, Hepatocellular*;
Cytokines;
Fibroblast Growth Factors;
Follow-Up Studies;
Hepatocyte Growth Factor;
Humans;
Inflammation;
Intercellular Signaling Peptides and Proteins;
Interleukin-17*;
Interleukins;
Platelet-Derived Growth Factor;
Prognosis;
Vascular Endothelial Growth Factor A
- From:Journal of Liver Cancer
2016;16(2):108-117
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Transarterial chemoembolization (TACE) is the standard locoregional treatment in patients with unresectable hepatocellular carcinoma (HCC). Angiogenesis and inflammation play important roles in tumor growth in HCC. In this study, we evaluated the associations between the levels of growth factors and inflammatory markers and clinical prognosis in patients with unresectable HCC treated with TACE. METHODS: The clinical outcomes of 58 HCC patients treated with TACE at the Catholic Medical Centers from January, 2012 to February 2015 were evaluated. Baseline levels of the growth factors vascular endothelial growth factor, fibroblast growth factor, platelet-derived growth factor, and hepatocyte growth factor and the inflammatory cytokines interleukin (IL)-17 and high sensitivity C-reactive protein (hs-CRP) were compared with the treatment outcomes. The primary endpoint was time to progression (TTP); the secondary endpoint was overall survival (OS). RESULTS: During the 20.8 months of follow-up, TTP was significantly delayed in patients with low levels of hs-CRP (≤0.15) and IL-17 (≤0.94) and a maximal tumor diameter ≤5 cm (P=0.010, P=0.015, and 0.048, respectively). Patients with HCC with low hs-CRP and IL-17 levels had a longer survival than that of those with high hs-CRP levels and IL-17 (35.1 vs. 22.5 months, P=0.000; 41 vs. 21.8 months, P=0.000, respectively). However, any baseline growth factors were not significantly correlated with TTP and OS. CONCLUSIONS: Elevated IL-17 and hs-CRP may be predictive of a poor outcome in patients with HCC treated with TACE. A better understanding of this relationship will require further investigation of the immune mechanisms underlying tumor progression.
